Panobinostat
Salivary Cancer
Genentech, Inc.Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Salivary Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ALECTINIB Genentech, Inc. | Phase 2 | B |
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Genentech, Inc. | Phase 2 | B |
Atezolizumab Genentech, Inc. | Phase 2 | B |
Gdc-0449 Genentech, Inc. | Phase 2 | B |
Cobimetinib Genentech, Inc. | Phase 2 | B |
VEMURAFENIB Genentech, Inc. | Phase 2 | CCC |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →